CMS has issued a product-specific J code for Photrexa formulations used in corneal collagen cross-linking, Avedro announced in a press release.
J2787 will become effective on Jan. 1, 2019, for Photrexa (riboflavin 5’-phosphate ophthalmic solution) and Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), the only FDA-approved drugs for use in cross-linking for patients with progressive keratoconus and cornea ectasia following refractive surgery.
“We expect the permanent J code to positively impact patients and physician practices by providing much
Uncategorized